JP2024528029A5 - - Google Patents
Info
- Publication number
- JP2024528029A5 JP2024528029A5 JP2024505205A JP2024505205A JP2024528029A5 JP 2024528029 A5 JP2024528029 A5 JP 2024528029A5 JP 2024505205 A JP2024505205 A JP 2024505205A JP 2024505205 A JP2024505205 A JP 2024505205A JP 2024528029 A5 JP2024528029 A5 JP 2024528029A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- optionally
- nucleic acid
- acid molecule
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163227116P | 2021-07-29 | 2021-07-29 | |
| US63/227,116 | 2021-07-29 | ||
| PCT/IB2022/057006 WO2023007431A1 (en) | 2021-07-29 | 2022-07-28 | Engineered immune cell that specifically targets mesothelin and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024528029A JP2024528029A (ja) | 2024-07-26 |
| JP2024528029A5 true JP2024528029A5 (cg-RX-API-DMAC10.html) | 2025-08-01 |
Family
ID=83457041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024505205A Pending JP2024528029A (ja) | 2021-07-29 | 2022-07-28 | メソテリンを特異的に標的とする操作された免疫細胞及びその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240350627A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4377335A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024528029A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240040068A (cg-RX-API-DMAC10.html) |
| CN (1) | CN117642421A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022318416A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3227581A1 (cg-RX-API-DMAC10.html) |
| TW (1) | TW202321287A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023007431A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202190624A1 (ru) * | 2018-08-31 | 2021-06-09 | Нойл-Иммьюн Байотек, Инк. | Car-экспрессирующие т-клетки и car-экспрессирующий вектор |
| WO2022092841A1 (ko) * | 2020-10-28 | 2022-05-05 | 주식회사 티에스디라이프사이언스 | 이종 면역세포에 대한 화학주성을 유도하는 형질전환된 면역세포 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4036945A (en) | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| JP2928287B2 (ja) | 1988-09-29 | 1999-08-03 | 協和醗酵工業株式会社 | 新規ポリペプチド |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US9272002B2 (en) | 2011-10-28 | 2016-03-01 | The Trustees Of The University Of Pennsylvania | Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
| SG10201806573TA (en) | 2012-05-25 | 2018-09-27 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| KR20240164967A (ko) | 2014-02-04 | 2024-11-21 | 카이트 파마 인코포레이티드 | B 세포 악성종양 및 다른 암을 치료하는데 유용한 자가 t 세포 및 그의 조성물의 생산 방법 |
| WO2016019300A1 (en) | 2014-07-31 | 2016-02-04 | Novartis Ag | Subset-optimized chimeric antigen receptor-containing t-cells |
| RS63601B1 (sr) * | 2014-10-09 | 2022-10-31 | Univ Yamaguchi | Vektor ekspresije car i t ćelije koje eksprimiraju car |
| RU2751362C2 (ru) * | 2014-12-29 | 2021-07-13 | Новартис Аг | Способы получения экспрессирующих химерный антигенный рецептор клеток |
| PT3393504T (pt) * | 2015-12-22 | 2025-12-30 | Novartis Ag | Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena |
| MX2018010974A (es) * | 2016-03-17 | 2019-03-28 | Univ Yamaguchi | Célula inmunocompetente y vector de expresión que expresa factores reguladores de la función inmune. |
| CA3075886A1 (en) * | 2017-10-10 | 2019-04-18 | Yamaguchi University | Enhancer for t-cells or b-cells having memory function, malignant tumor recurrence inhibitor, and inducer for inducing memory function in t-cells or b-cells |
| WO2019099707A1 (en) * | 2017-11-16 | 2019-05-23 | Kite Pharma, Inc | Modified chimeric antigen receptors and methods of use |
| MX428412B (es) * | 2017-12-24 | 2025-11-13 | Noile Immune Biotech Inc | Celula inmunocompetente que expresa una molecula de superficie celular que reconoce especificamente la mesotelina humana, il-7 y ccl19 |
| IL292542B2 (en) * | 2019-10-28 | 2025-11-01 | Noile Immune Biotech Inc | Drug for treating cancer, combination drug, drug composition, immune responsive cell, nucleic acid delivery vehicle, and product |
-
2022
- 2022-07-28 US US18/292,586 patent/US20240350627A1/en active Pending
- 2022-07-28 CN CN202280050120.5A patent/CN117642421A/zh active Pending
- 2022-07-28 CA CA3227581A patent/CA3227581A1/en active Pending
- 2022-07-28 KR KR1020247000845A patent/KR20240040068A/ko active Pending
- 2022-07-28 WO PCT/IB2022/057006 patent/WO2023007431A1/en not_active Ceased
- 2022-07-28 EP EP22777698.6A patent/EP4377335A1/en active Pending
- 2022-07-28 JP JP2024505205A patent/JP2024528029A/ja active Pending
- 2022-07-28 AU AU2022318416A patent/AU2022318416A1/en active Pending
- 2022-07-28 TW TW111128411A patent/TW202321287A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250034244A1 (en) | Bicistronic chimeric antigen receptors and their uses | |
| JP2024528052A5 (cg-RX-API-DMAC10.html) | ||
| CN110872577B (zh) | 修饰的免疫细胞及其应用 | |
| JP6426713B2 (ja) | Ｇｐｃ３キメラ抗原受容体蛋白質をコードする核酸及びｇｐｃ３キメラ抗原受容体蛋白質を発現するｔリンパ球 | |
| AU2019235926A1 (en) | Anti-CD33 chimeric antigen receptors and their uses | |
| CN115698072B (zh) | 抗gpc3抗体，抗gpc3嵌合抗原受体和gpc3/cd3双特异性抗体 | |
| WO2017219936A1 (zh) | 一种高效稳定表达激活型抗体的car-t细胞及其用途 | |
| CN111349178A (zh) | 一种靶向gpc3的嵌合抗原受体(car)及其抗癌的用途 | |
| JP2022525099A5 (cg-RX-API-DMAC10.html) | ||
| Li et al. | Chimeric antigen receptor-immune cells against solid tumors: Structures, mechanisms, recent advances, and future developments | |
| CN108367068A (zh) | 用于治疗白血病的抗-s100a8 | |
| CN111944054A (zh) | 抗bcma的car及其表达载体和应用 | |
| JP2024510898A (ja) | Ｒｏｒ１を標的とするキメラ抗原受容体 | |
| CN110386987A (zh) | 一种抑制性的合成Notch和双靶点系统及其制备方法和应用 | |
| CN116568709A (zh) | 靶向cd5的全人源抗体、全人源嵌合抗原受体（car）及其应用 | |
| CN116284419A (zh) | 靶向人gucy2c蛋白的单克隆抗体及其应用 | |
| CN116554327A (zh) | 特异性结合c-Met的抗体、嵌合抗原受体及其应用 | |
| CN117003897B (zh) | 靶向Claudin18.2的CAR-T细胞及其用途 | |
| TW202003854A (zh) | 抗人ｌａｇ－３單克隆抗體及其應用 | |
| CN111944053B (zh) | 抗bcma的car及其表达载体和应用 | |
| CN114685675B (zh) | 双特异性抗体及其在治疗癌症中的用途 | |
| CN120882754A (zh) | 用淋巴毒素β受体激动剂治疗癌症的方法 | |
| Pantuck et al. | Next generation T-cell therapy for genitourinary malignancies, part A: Introduction and current state of the art | |
| WO2023076811A1 (en) | Combination therapies with chimeric antigen receptors | |
| JP2023521218A (ja) | Ｃｄ２２標的キメラ抗原受容体、その調製方法、及びその適用 |